For pharma companies, the weeks immediately before and after FDA submission are critical to launch success. During this pivotal period, missteps can result in several undesirable outcomes at launch, from overestimating your brand’s adoption peak to underestimating the necessary contracting spend.
In this webinar, we’ll discuss five of the largest risks associated with launch. Our experts will explain the concrete steps your team can take to mitigate those risks in advance—so you can launch your therapy without fear of failure.
You will learn:
